Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new web tool has been developed to simplify the prescription of antidepressant and antipsychotic drugs.

Psymatik treatment optimizer website tool to help identify treatments

Researchers from the University of Oxford and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London hope the move will empower patients to have a more active role in choosing the medication that they take.  

The release of the web tool, the Psymatik Treatment Optimizer, has been accompanied by the publication of an umbrella review in Lancet Psychiatry. Researchers reviewed all available data on 69 medications – 32 antipsychotics and 37 antidepressants – which was then used to create a database of side effects and effectiveness of each one. 

The National Institute for Health and Care Excellence (NICE) prescribing guidelines for antidepressants and antipsychotics recommend that patient and doctor have a conversation about the effectiveness and side effects of different medications before prescribing. However, due to the number of drugs available, and the wide array of potential side effects, meaningful conversations about the medications on offer are difficult and often limited to only a few options. 

Prior to making a choice about which drug to prescribe, doctor and patient sit down to discuss the various potential side effects that the patient is most concerned about. The doctor inputs this information into the Optimizer, which then provides a clear table on which antidepressant is least likely to cause that side effect, balanced against its effectiveness as a medication. 

Dr Robert McCutcheon, Wellcome Clinical Career Development Fellow at the University of Oxford and the study’s senior author, said:

Helping an individual choose a medication that is right for them is absolutely crucial, and optimising the balance of side effects is key to helping people stick with treatments than help their symptoms.

We have compiled that most comprehensive side effect database for antidepressants and antipsychotics that streamlines the prescribing process while also empowering patients to make the decisions that are right for them.”  

Dr Toby Pillinger, a Clinical Lecturer at King’s IoPPN and the study’s first author, explains: “The Psymatik Treatment Optimizer allows patients and their doctors to easily establish which side effects the patient is most worried about, allowing both parties to quickly highlight which medication is likely to work best. 

“A patient might, for example, feel reluctant to engage with a course of medication due to the significant amount of weight they gained the last time that type of medication was prescribed. Our database takes that information and plots out a series of alternatives, setting the groundwork for a much more transparent conversation about the prescribing process.” 

This research is supported by funding from the National Institute for Health and Care Research (NIHR) and Maudsley Charity. 

 

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Semaglutide associated with fewer cognitive problems in people with mental illness

Semaglutide, widely used to treat diabetes and obesity, was associated with fewer cognitive signs and symptoms in people with psychiatric disorders, according to a new study led by researchers at the University of Oxford.

New audit system maps how mental-health risks emerge in AI chatbot conversations

Scientists have developed a framework for stress-testing how AI chatbots respond to vulnerable users, helping researchers identify weaknesses and test ways of making mental-health interactions safer.

AI could help identify patients at risk of psychosis more quickly

AI has been shown to be effective in identifying and analysing symptoms from psychiatric interviews, which could help speed up assessments and access to care for those who need it most, according to a new study.

Infections linked to higher risk of brain and mental health conditions for up to two years

A large study of more than 1 million matched patient pairs finds that serious infections across the body are followed by increased risks of psychiatric and neurological diagnoses, especially in adults

Salsa classes shown to reduce depressive symptoms in young adults

A new trial led by the University of Oxford suggests it may offer a promising, accessible addition to youth wellbeing support.

Clinical Trial of Ketogenic Therapy for Early Psychosis funded by Baszucki Group

The University Oxford has received £1.17m of funding from Baszucki Group to assess the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P).